Super-Enhancer LncRNA LINC00162 Promotes Progression of Bladder Cancer

• Main Authors: Xin Wang, Ruirui Zhang, Shuilian Wu, Liping Shen, Meixia Ke, Yan Ouyang, Mengqi Lin, Yiting Lyu, Binuo Sun, Zhijian Zheng, Jialei Yang, Jie Yang, Wenmin Lu, Yiping Yang, Danni Li, Yunfeng Zou, Haishan Huang, Aruo Nan
• Format: Article
• Language: English
• Published: Elsevier 2020-12-01
• Series: iScience
• Subjects: Molecular Biology; Cancer
• Online Access: http://www.sciencedirect.com/science/article/pii/S2589004220310543

Summary: Due to the lack of effective early diagnostic measures and treatment methods, bladder cancer has become a malignant tumor that seriously threatens people's lives and health. Here, we reported that LINC00162, a super-enhancer long noncoding RNA, was highly expressed in bladder cancer cells and tissues. And LINC00162 was negatively correlated with neighboring PTTG1IP expression. Knocking down LINC00162 expression can inhibit the proliferative activity of bladder cancer cells and the growth of transplanted tumors in vivo, while knocking down the expression of PTTG1IP could restore the proliferative activity of bladder cancer cells. In addition, both LINC00162 and PTTG1IP were found to be able to bind to THRAP3, a transcription-related protein. And THRAP3 can regulate PTTG1IP expression. Finally, we demonstrated a mechanism that LINC00162 could regulate PTTG1IP expression through binding THRAP3. This study provided a potential target molecule for clinical treatment of bladder cancer.